Relapsing Multiple Sclerosis Clinical Trials in Washington D.C., District of Columbia
3 recruitingWashington D.C., District of Columbia
Showing 1–3 of 3 trials
Recruiting
Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled99 locationsNCT06846281
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.500 enrolled85 locationsNCT06433752
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963